• Jefferies sets a modest price target increase for Moderna, Inc. (NASDAQ: MRNA), indicating a potential 1.28% growth.
• Investment firm Amundi significantly reduces its stake in Moderna, contrasting with other firms like Natixis Advisors LLC and Charles Schwab Investment Management Inc., which increased their holdings.
• Despite varying investment strategies, Moderna's stock price has experienced a 2.03% increase, with a market capitalization of approximately $11.57 billion.

Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing COVID-19 vaccines. The company competes with other pharmaceutical giants like Pfizer and BioNTech. On December 11, 2025, Jefferies set a price target of $30 for Moderna, slightly above its current price of $29.62, indicating a modest 1.28% potential increase.

Amundi, a major investment firm, has reduced its stake in Moderna by 31.9%, selling 425,861 shares. This leaves Amundi with 909,429 shares, valued at $27.5 million, representing about 0.23% of Moderna. This reduction contrasts with other firms like Natixis Advisors LLC, which increased its stake by 70.7%, now holding 17,761 shares valued at $504,000.

Charles Schwab Investment Management Inc. also expanded its position in Moderna by 12.2%, now owning 2,629,865 shares worth $74.6 million. These differing investment strategies highlight varying confidence levels in Moderna's future performance. Despite these changes, Moderna's stock price has seen a 2.03% increase, reaching $29.62.

The stock has fluctuated between $28.87 and $29.66 today, with a 52-week high of $48.92 and a low of $22.28. Moderna's market capitalization is approximately $11.57 billion, with a trading volume of 7,159,436 shares on the NASDAQ exchange. These figures reflect the market's dynamic response to investment shifts and price target announcements.